Ancylostomiasis medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 16: | Line 16: | ||
**'''Pediatric''' | **'''Pediatric''' | ||
***'''children <2 years of age''' | ***'''children <2 years of age''' | ||
Currently, for the [[treatment]] of young [[infants]], no guidelines are [[available]]. But current [[knowledge]] shows that the [[side effects]] linked to [[benzimidazole]] drugs in young children are likely to be the same as in older [[children]] and [[adults]]. Therefore, for the [[potential]] [[benefit]] of [[physical]] and [[cognitive development]], the [[treatment]] of [[young infants]] could be [[justified]].<ref name="pmid12745139">{{cite journal| author=Montresor A, Awasthi S, Crompton DW| title=Use of benzimidazoles in children younger than 24 months for the treatment of soil-transmitted helminthiasis. | journal=Acta Trop | year= 2003 | volume= 86 | issue= 2-3 | pages= 223-32 | pmid=12745139 | doi=10.1016/s0001-706x(03)00042-1 | pmc=5633076 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12745139 }} </ref> | ****Currently, for the [[treatment]] of young [[infants]], no guidelines are [[available]]. But current [[knowledge]] shows that the [[side effects]] linked to [[benzimidazole]] drugs in young children are likely to be the same as in older [[children]] and [[adults]]. Therefore, for the [[potential]] [[benefit]] of [[physical]] and [[cognitive development]], the [[treatment]] of [[young infants]] could be [[justified]].<ref name="pmid12745139">{{cite journal| author=Montresor A, Awasthi S, Crompton DW| title=Use of benzimidazoles in children younger than 24 months for the treatment of soil-transmitted helminthiasis. | journal=Acta Trop | year= 2003 | volume= 86 | issue= 2-3 | pages= 223-32 | pmid=12745139 | doi=10.1016/s0001-706x(03)00042-1 | pmc=5633076 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12745139 }} </ref> | ||
==References== | ==References== | ||
Revision as of 11:43, 19 August 2021
|
Ancylostomiasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ancylostomiasis medical therapy On the Web |
|
American Roentgen Ray Society Images of Ancylostomiasis medical therapy |
|
Risk calculators and risk factors for Ancylostomiasis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
Anti-helminthic therapies are recommended among patients with ancylostomiasis. Efficacy of treatment varies according to the severity of infection, geographical distribution, and age groups.[1]
- For stable uncomplicated cases
- Adult
- Preferred regimen: Albendazole 400 mg PO single dose
- Alternative regimen: Mebendazole 100 mg PO q12h for 3 days
- Alternative regimen: Pyrantel Pamoate 11mg/kg PO q24h for 3 days (maximum, 1gm per dose)
- Pediatric
- children <2 years of age
- Currently, for the treatment of young infants, no guidelines are available. But current knowledge shows that the side effects linked to benzimidazole drugs in young children are likely to be the same as in older children and adults. Therefore, for the potential benefit of physical and cognitive development, the treatment of young infants could be justified.[2]
- children <2 years of age
- Adult
References
- ↑ Loukas A, Hotez PJ, Diemert D, Yazdanbakhsh M, McCarthy JS, Correa-Oliveira R; et al. (2016). "Hookworm infection". Nat Rev Dis Primers. 2: 16088. doi:10.1038/nrdp.2016.88. PMID 27929101.
- ↑ Montresor A, Awasthi S, Crompton DW (2003). "Use of benzimidazoles in children younger than 24 months for the treatment of soil-transmitted helminthiasis". Acta Trop. 86 (2–3): 223–32. doi:10.1016/s0001-706x(03)00042-1. PMC 5633076. PMID 12745139.